{"nctId":"NCT01023308","briefTitle":"Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma","startDateStruct":{"date":"2009-12-21","type":"ACTUAL"},"conditions":["Multiple Myeloma"],"count":767,"armGroups":[{"label":"Panobinostat + Bortezomib + Dexamethasone","type":"EXPERIMENTAL","interventionNames":["Drug: Panobinostat","Drug: Bortezomib","Drug: Dexamethasone"]},{"label":"Placebo + Bortezomib + Dexamethasone","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Bortezomib","Drug: Dexamethasone","Drug: Placebo"]}],"interventions":[{"name":"Panobinostat","otherNames":["LBH589"]},{"name":"Bortezomib","otherNames":["(VelcadeÂ®)"]},{"name":"Dexamethasone","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Patient has a previous diagnosis of multiple myeloma.\n2. Patient requires retreatment for multiple myeloma\n3. Patient has measurable M component in serum or urine at study screening\n\nExclusion Criteria:\n\n1. Patient who has progressed under all prior lines of anti MM therapy\n2. Patient who has been treated by bortezomib before, and did not reach at least a minor response under this therapy, or progressed under it or within 60 days of last dose\n3. Patient has shown intolerance to bortezomib or to dexamethasone or components of these drugs or has any contraindication to one or the other drug , following locally applicable prescribing information\n4. Patient received prior treatment with DAC inhibitors including panobinostat\n5. Patient has impaired cardiac function, or a prolonged QTc interval at screening ECG\n6. Patient taking medications with relative risk of prolonging the QT interval or inducing Torsade de pointes\n7. Female patient who is pregnant or breast feeding or with childbearing potential and not willing to use a double method of contraception up to 3 months after the end of study treatment. Male patient who is not willing to use a barrier method of contraception up to 3 months after the end of study treatment.\n\nOther protocol-defined inclusion/exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-free Survival Events in Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"207","spread":null},{"groupId":"OG001","value":"260","spread":null}]}]}]},{"type":"PRIMARY","title":"Progression Free Survival in Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.99","spread":null},{"groupId":"OG001","value":"8.80","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival in Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone","description":"Number of OS events","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"134","spread":null},{"groupId":"OG001","value":"152","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival in Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone","description":"survival time in months","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.28","spread":null},{"groupId":"OG001","value":"35.78","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Response Rate in Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone.","description":"Best overall response based on mEBMT criteria per investigator assessment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.7","spread":null},{"groupId":"OG001","value":"54.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Response Per Investigator Assessment (mEBMT Criteria) of Response Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.51","spread":null},{"groupId":"OG001","value":"2.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Response Per Investigator Assessment (mEBMT Criteria) Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.14","spread":null},{"groupId":"OG001","value":"10.87","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Progression/Relapse Per Investigator Assessment (mEBMT Criteria) Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.71","spread":null},{"groupId":"OG001","value":"8.54","spread":null}]}]}]},{"type":"SECONDARY","title":"European Organization for Research and Treatment of Cancer Multiple Myeloma Module (EORTC) QLQ-MY20-Change From Baseline by Treatment Group","description":"Higher values in the disease symptoms and side effects of treatment scores indicate worsening. Higher scores in the future perspective and body image scores indicate improvement. LS Means and SEM are estimated from the repeated measures model. Following factors and covariates are included in the repeated measurement model: time, treatment, treatment by time interaction, number of prior lines of anti-MM therapy (1/ 2 and 3), prior use of BTZ (Yes/ No), baseline score.Disease Symptom is the sum of 20 questions, total score ranges from 0 (best possible outcome) to 100 (worst possible outcome)\", All subscales of EORTC QLQ-MY20 have the same score range of 0 -100. Decrease in symptom scores from baseline indicate improvement in symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.795","spread":null},{"groupId":"OG001","value":"-4.865","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.401","spread":null},{"groupId":"OG001","value":"-6.797","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.836","spread":null},{"groupId":"OG001","value":"-6.626","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.162","spread":null},{"groupId":"OG001","value":"5.524","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.016","spread":null},{"groupId":"OG001","value":"7.731","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.357","spread":null},{"groupId":"OG001","value":"3.654","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.319","spread":null},{"groupId":"OG001","value":"6.194","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.877","spread":null},{"groupId":"OG001","value":"5.839","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.331","spread":null},{"groupId":"OG001","value":"6.951","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.178","spread":null},{"groupId":"OG001","value":"-6.22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.463","spread":null},{"groupId":"OG001","value":"-7.358","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.161","spread":null},{"groupId":"OG001","value":"-4.666","spread":null}]}]}]},{"type":"SECONDARY","title":"European Organization for Research and Treatment of Cancer Multiple Myeloma Module (EORTC ) QLQ-C30 - Summary Statistics by Treatment Group","description":"The EORTC QLQ-C30 measures functional dimensions (physical, role, emotional, cognitive, and social), three multi-item symptom scales (fatigue, nausea/vomiting, and pain), six single-item symptom scales (dyspnea, sleep disturbance, appetite loss, constipation, diarrhea and financial impact) and a global health status/QoL scale. Disease Symptom is the sum of 30 questions, total score ranges from 0 (best possible outcome) to 100 (worst possible outcome)\", All subscales of EORTC QLQ-C30 have the same score range of 0 -100. For global health status and other functional scales,an increase from baseline indicates improvement of QoL. Whereas for symptoms scales, fatigue, dyspnea, insomnia, appetite loss, constipation and diarrhea, decrease in scores from baseline indicate improvement in symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.853","spread":null},{"groupId":"OG001","value":"-4.044","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.867","spread":null},{"groupId":"OG001","value":"-1.518","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.986","spread":null},{"groupId":"OG001","value":"4.345","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.67","spread":null},{"groupId":"OG001","value":"-5.393","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.516","spread":null},{"groupId":"OG001","value":"-6.456","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.88","spread":null},{"groupId":"OG001","value":"2.037","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.159","spread":null},{"groupId":"OG001","value":"-6.762","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.875","spread":null},{"groupId":"OG001","value":"-11.263","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.927","spread":null},{"groupId":"OG001","value":"-0.401","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.464","spread":null},{"groupId":"OG001","value":"-1.023","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.053","spread":null},{"groupId":"OG001","value":"-3.542","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.568","spread":null},{"groupId":"OG001","value":"-4.042","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.502","spread":null},{"groupId":"OG001","value":"-3.991","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.925","spread":null},{"groupId":"OG001","value":"-6.338","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.104","spread":null},{"groupId":"OG001","value":"4.617","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.122","spread":null},{"groupId":"OG001","value":"7.939","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.677","spread":null},{"groupId":"OG001","value":"9.203","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.646","spread":null},{"groupId":"OG001","value":"-2.625","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.964","spread":null},{"groupId":"OG001","value":"6.266","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.939","spread":null},{"groupId":"OG001","value":"5.308","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.118","spread":null},{"groupId":"OG001","value":"2.82","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.283","spread":null},{"groupId":"OG001","value":"7.625","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.023","spread":null},{"groupId":"OG001","value":"6.104","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.464","spread":null},{"groupId":"OG001","value":"-3.442","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.167","spread":null},{"groupId":"OG001","value":"5.383","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.574","spread":null},{"groupId":"OG001","value":"5.861","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.999","spread":null},{"groupId":"OG001","value":"-2.963","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.135","spread":null},{"groupId":"OG001","value":"6.42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.153","spread":null},{"groupId":"OG001","value":"0.524","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.358","spread":null},{"groupId":"OG001","value":"-0.946","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.888","spread":null},{"groupId":"OG001","value":"10.206","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.163","spread":null},{"groupId":"OG001","value":"16.406","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.48","spread":null},{"groupId":"OG001","value":"10.996","spread":null}]}]}]},{"type":"SECONDARY","title":"Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System : FACT/GOG-NTX-Change From Baseline by Treatment Group","description":"Chronic Illness Therapy (FACIT) Measurement System and focuses on four general quality of life domains for physical well being, functional well-being, social/family well-being, and emotional well-being, and includes additional items to characterize treatment-related neurotoxicity. Higher subscales/total scores represent higher QOL. In the case of the neurotoxicity subscale, lower scores correspond to higher neurotoxicity. The recall period referenced in the questionnaire is the past 7 days.Ranges for FACT-G subscales are as follows:.PWB, scale 0 -28, , NtxS scale 0-44, FACT/GOG-Ntx trial outcome index scale is 0-100 and FACT-G scale is also scaled 0-100. An increase from baseline in these scores indicate improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.481","spread":null},{"groupId":"OG001","value":"-3.337","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.564","spread":null},{"groupId":"OG001","value":"-4.739","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.158","spread":null},{"groupId":"OG001","value":"-2.133","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.29","spread":null},{"groupId":"OG001","value":"-1.952","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.044","spread":null},{"groupId":"OG001","value":"-2.259","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.037","spread":null},{"groupId":"OG001","value":"0.203","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.573","spread":null},{"groupId":"OG001","value":"-6.874","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.84","spread":null},{"groupId":"OG001","value":"-8.894","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.633","spread":null},{"groupId":"OG001","value":"-2.821","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.658","spread":null},{"groupId":"OG001","value":"-4.106","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.076","spread":null},{"groupId":"OG001","value":"-4.609","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.704","spread":null},{"groupId":"OG001","value":"-1.435","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.176","spread":null},{"groupId":"OG001","value":"-7.524","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.581","spread":null},{"groupId":"OG001","value":"-9.179","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.871","spread":null},{"groupId":"OG001","value":"-3.151","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":228,"n":381},"commonTop":["Diarrhoea","Thrombocytopenia","Anaemia","Fatigue","Neuropathy peripheral"]}}}